Product
casirivimab+imdevimab
Aliases
REGEN-COV™, REGN10933, REGN10987, REGN-COV2 (1 other aliases)
3 clinical trials
4 indications
Indication
COVID-19Indication
ImmunocompromisedIndication
HealthyIndication
Chronic Stable IllnessClinical trial
A Phase 2A, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti- Spike(s) SARS-COV-2 Monoclonal Antibodies (Casirivimab and Imdevimab) in High-Risk Pediatric Subjects Under 12 Years of AgeStatus: Terminated, Estimated PCD: 2022-06-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised ParticipantsStatus: Terminated, Estimated PCD: 2022-05-18
Clinical trial
A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2022-11-21